Valiant Laboratories Ltd. AI Stock Analysis
Want to see IN:VALIANTLAB full AI Analyst Report?
Valiant Laboratories Ltd. (VALIANTLAB) AI Stock Analysis
Valiant Laboratories Ltd.
(NSE:VALIANTLAB)
The overall score is constrained by poor financial fundamentals, including negative cash flows and margins, and an expensive valuation with a high P/E ratio. However, strong bullish technical momentum significantly lifts the score, suggesting the market is pricing in a future turnaround that has not yet materialized in the financials.
Valiant Laboratories Ltd. (VALIANTLAB) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 5.48B
- Dividend Yield
- ―
- Average Volume (3M)
- 15.14K
- Price to Earnings (P/E)
- 33.8
- Beta (1Y)
- 0.27
- Revenue Growth
- 102.37%
- EPS Growth
- 176.45%
- Country
- India
- Employees
- 84
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Valiant Laboratories Ltd. Business Overview & Revenue Model
Company Description
Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in vario...
How the Company Makes Money
Valiant Laboratories Ltd. makes money primarily by manufacturing and selling active pharmaceutical ingredients (APIs) to customers in the pharmaceutical supply chain (such as finished-dosage manufacturers and formulators). Its core revenue stream is...
Valiant Laboratories Ltd. Financial Statement Overview
Summary
Financial performance is weak. The Income Statement (Score 30) shows margin compression and net losses, and Cash Flow (Score 25) is deeply negative, raising liquidity concerns. These are partially offset by a solid Balance Sheet (Score 75) with low debt. Overall, profitability and cash generation are significant drags.
Income Statement
30NegativeBalance Sheet
75PositiveCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.77B | 2.37B | 1.39B | 1.82B | 3.34B | 2.92B |
| Gross Profit | 731.87M | 272.66M | 222.17M | 115.76M | 390.07M | 523.21M |
| EBITDA | 385.24M | 87.11M | 7.55M | -84.08M | 399.53M | 442.67M |
| Net Income | 162.19M | -32.68M | -22.01M | 3.20M | 289.98M | 274.96M |
Balance Sheet | ||||||
| Total Assets | 4.54B | 4.64B | 4.01B | 3.43B | 2.13B | 1.82B |
| Cash, Cash Equivalents and Short-Term Investments | 369.49M | 331.50M | 759.91M | 1.44B | 353.61M | 205.33M |
| Total Debt | 377.84M | 462.12M | 1.22B | 767.08M | 602.17M | 611.26M |
| Total Liabilities | 1.22B | 1.53B | 1.67B | 1.06B | 1.12B | 1.10B |
| Stockholders Equity | 3.32B | 3.11B | 2.34B | 2.37B | 1.00B | 714.60M |
Cash Flow | ||||||
| Free Cash Flow | 0 | -471.97M | -1.13B | -439.85M | 183.70M | -46.25M |
| Operating Cash Flow | 0 | -129.97M | 13.13M | 18.85M | 560.51M | 22.51M |
| Investing Cash Flow | 0 | 72.52M | -527.68M | -1.44B | -551.68M | -122.38M |
| Financing Cash Flow | 0 | 43.57M | 446.53M | 1.52B | -9.34M | 61.81M |
Valiant Laboratories Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VALIANTLAB, the sentiment is Negative. The current price of 103.25 is below the 20-day moving average (MA) of 120.93, below the 50-day MA of 121.14, and above the 200-day MA of 81.46, indicating a neutral trend. The MACD of -4.51 indicates Positive momentum. The RSI at 29.00 is Positive, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VALIANTLAB.
Valiant Laboratories Ltd. Peers Comparison
Overall Rating
IN:MEDICAMEQ64Neutral
IN:MEDICO63Neutral
IN:BAFNAPH60Neutral
IN:VALIANTLAB56Neutral
IN:ALBERTDAVD54Neutral
IN:ZIMLAB52.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 64Neutral | INR 3.99B | 32.55 | ― | 0.34% | 27.47% | 6.56% | |
| 63Neutral | INR 1.55B | 11.25 | ― | ― | 50.78% | 20.08% | |
| 60Neutral | INR 11.36B | 98.77 | ― | ― | 8.74% | 31.20% | |
| 56Neutral | INR 5.61B | 33.76 | ― | ― | 102.37% | 176.45% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | INR 4.39B | 15.26 | ― | 0.64% | 19.69% | ― | |
| 53Neutral | INR 7.29B | 256.58 | ― | ― | 13.14% | -60.77% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:VALIANTLAB | Valiant Laboratories Ltd. | 103.25 | 26.09 | 33.81% | |
| IN:ALBERTDAVD | Albert David Ltd | 770.00 | -28.20 | -3.53% | |
| IN:BAFNAPH | Bafna Pharmaceuticals Limited | 480.00 | 305.70 | 175.39% | |
| IN:MEDICAMEQ | Medicamen Biotech Limited | 293.85 | -109.34 | -27.12% | |
| IN:MEDICO | Medico Remedies Ltd. | 18.73 | -34.59 | -64.87% | |
| IN:ZIMLAB | Zim Laboratories Ltd. | 135.85 | 61.68 | 83.16% |
Valiant Laboratories Ltd. Corporate Events
Valiant Laboratories to Hold 5th AGM via Video Conferencing with Full E-Voting Access
Valiant Laboratories Ltd., a Mumbai-based listed pharmaceutical and chemical manufacturer, engages with a broad shareholder base through India’s main stock exchanges. The company’s operations are shaped by stringent regulatory requirements, and it in...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 10, 2026
